Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Et sikkerheds- og effektivitetsstudie af hu14 hos patienter med højrisiko neuroblastom (SHINE)

19. november 2026 opdateret af: Renaissance Pharma Ltd.

Et fase 2/3-studie til karakterisering og evaluering af effekt, sikkerhed og tolerabilitet af hu14.18K322A-behandling givet i kombination med kemoterapi til deltagere med højrisiko-neuroblastom

Neuroblastoma is the most common type of solid cancer found outside the brain in young children. Generally, it affects children younger than 5 years old, with the average age when it is found being just 2 years. Most patients have 'high-risk' disease, with spread of the disease to different sites (metastases). This multinational study aims to find out how effective and safe the treatment of a monoclonal anti-GD2 antibody hu14.18K322A (daretabart) is when used together with chemotherapy to treat children and young people who have high-risk neuroblastoma.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This is a Phase 2/3, open label, single arm study, evaluating how well hu14.18K322A works and how safe it is in combination with chemotherapy, in relapsed and refractory high-risk neuroblastoma (HRNB) patients.

The study is in 2 parts. The first part of the study will test two doses of hu14.18K322A to give with chemotherapy in 12 patients to confirm the best dose. Once the best dose is found, Part 2 of the study will recruit up to an additional 66 participants with relapsed disease and 66 participants with refractory disease.

Children and young people who take part in the study must be between 18 months and 18 years old at the time of consent and have confirmed HRNB that has spread to other parts of the body. It is expected that participants will receive up to 12 cycles of treatment. Once the treatment has finished, participants will be followed up to study long-term effects.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

144

Fase

  • Fase 2
  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Ontario
      • Toronto, Ontario, Canada, M5G 1E8
        • Rekruttering
        • The Hospital for Sick Children
        • Kontakt:
      • Copenhagen, Danmark, 2100
      • Newcastle upon Tyne, Det Forenede Kongerige, NE1 4LP
      • Sutton, Det Forenede Kongerige, SM2 5PT
        • Rekruttering
        • Royal Marsden NHS Foundation Trust
        • Kontakt:
    • Hampshire
      • Southampton, Hampshire, Det Forenede Kongerige, SO16 6YD
        • Rekruttering
        • Southampton Children's Hospital
        • Kontakt:
    • California
      • San Francisco, California, Forenede Stater, 94143
        • Rekruttering
        • University of California San Francisco (UCSF)
        • Kontakt:
    • Colorado
      • Aurora, Colorado, Forenede Stater, 80045
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60637
        • Rekruttering
        • The University of Chicago
        • Kontakt:
    • Minnesota
      • Minneapolis, Minnesota, Forenede Stater, 55454
        • Rekruttering
        • University of Minnesota Masonic Children's Hospital
        • Kontakt:
    • New York
      • The Bronx, New York, Forenede Stater, 10467
        • Rekruttering
        • The Children's Hospital at Montefiore
        • Kontakt:
    • North Carolina
      • Durham, North Carolina, Forenede Stater, 27705
        • Rekruttering
        • Duke University Medical Center
        • Kontakt:
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forenede Stater, 19104
        • Rekruttering
        • Children's Hospital of Philadelphia
        • Kontakt:
    • Texas
      • Dallas, Texas, Forenede Stater, 75390
      • Marseille, Frankrig, 13005
      • Paris, Frankrig, 75005
        • Rekruttering
        • Institut Curie
        • Kontakt:
      • Villejuif, Frankrig, 94800
      • Barcelona, Spanien, 08035
        • Rekruttering
        • University Hospital Vall d'Hebron
        • Kontakt:
      • Barcelona, Spanien, 08950
        • Rekruttering
        • Hospital Sant Joan de Deu
        • Kontakt:
      • Madrid, Spanien, 28009
        • Rekruttering
        • Hospital Infantil Universitario Niño Jesús
        • Kontakt:
      • Valencia, Spanien, 46026
        • Rekruttering
        • Unidad De Oncohematologia Pediatrica
        • Kontakt:
      • Berlin, Tyskland, 13353
        • Rekruttering
        • Charité - Universitätsmedizin Berlin
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

1 år til 18 år (Barn, Voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria

  1. Are ≥18 months to <18 years of age at time of informed consent or assent.

  2. Are initially diagnosed with histologically proven HRNB with metastatic disease.

  3. Have evaluable or measurable disease per International Neuroblastoma Response Criteria (INRC)

  4. Have a Lansky performance status of ≥50 (≤16 years ) or Karnofsky performance status ≥50% (for >16 years).

  5. Have recovered from the toxic effects of prior chemotherapies

  6. Are at least 2 weeks beyond any major tumor surgery

  7. Meet the following organ function criteria, as measured within 1 week prior to Investigational Medicinal Product (IMP) dosing:

    1. BM function: i. Platelets ≥50 × 109/L ii. Absolute neutrophil count (ANC) ≥0.50 × 109/L
    2. Renal function: i. Age-adjusted serum creatinine ≤1.5 × upper limit of normal (ULN) for age. ii. Estimated glomerular filtration rate (eGFR) at least 60 mL/min using the Schwartz formula.
    3. Liver function: Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤3 × ULN and total bilirubin ≤1.5 × ULN.
    4. Cardiac function: i. Shortening fraction ≥27% or ejection fraction of ≥50% on echocardiogram. ii. Corrected QT Interval on electrocardiogram (ECG) using the Fridericia formula (QTcF) ≤ 480 msec.
    5. Lung function: i. Pulse oximetry considered normal in room air. No evidence of dyspnea at rest.
    6. Central nervous system (CNS) function: i. Participants with a history of CNS disease must have no clinical or radiological evidence of active CNS disease at the time of study enrollment.
  8. If a fertile and sexually active woman of child-bearing potential (WOCBP), have a negative serum pregnancy test at Screening and then either a negative serum or urine test prior to each cycle and agree to use an acceptable and highly effective contraception method during the study and for at least 6 months after the last day of study treatment .

  9. If a fertile and sexually active male, agree to use condoms during the study and for at least 6 months after the last dose of study treatment

  10. If applicable based on age, are willing and able to provide voluntary written informed assent for participation in the study (as per local Institutional Review Board [IRB]/Independent Ethics Committee [IEC] requirements and if applicable based on regional age of consent) and to comply with all protocol requirements.

  11. Their parent or legal guardian (if applicable based on regional age of consent) is willing and able to provide voluntary written informed consent for the participant's involvement in the study.

Exclusion Criteria

  1. Any active uncontrolled infection at the time of enrollment. Any known history of infection with human immunodeficiency virus (HIV), or active or chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).

  2. Any contraindications to any of the study treatments.

  3. Patients with >Grade 2 diarrhea.

  4. Patients with disease of any major organ system that would compromise their ability to withstand chemoimmunotherapy.

  5. Patients who have undergone a prior allogeneic stem cell transplant < 6 months ago or have undergone a solid organ transplant.

  6. Patients who are on hemodialysis.

  7. Patients who require or are likely to require pharmacologic doses of systemic corticosteroids while receiving treatment on this study except to manage allergic reactions

  8. Patients on any other immunosuppressive medications

  9. Patients who have received enzyme-inducing anticonvulsants including phenytoin, phenobarbital, or carbamazepine for at least 7 days prior to study enrollment.

  10. Patients who have been diagnosed with any malignancy other than neuroblastoma.

  11. Patients with symptoms of congestive heart failure.

  12. Patients with a history of Grade 4 allergic reactions to anti-GD2 antibodies or reactions that required permanent discontinuation of the anti-GD2 therapy.

  13. Patients participating in or planning to participate in another study that is either blinded or involves an IMP

  14. If female, are breastfeeding, pregnant, or planning to become pregnant, or, if sexually active and of child-bearing potential, are unwilling to use an effective birth control method until 6 months after the last dose of study medication

  15. Do not meet the following required washout periods prior to the administration of the first dose of hu14.18K322A:

    1. 14 days from prior systemic myelosuppressive chemotherapy.
    2. 7 days from prior systemic biologic antineoplastic agents (e.g. anti-cancer agents not known to be myelosuppressive - not associated with reduced platelet or ANC counts).
    3. 14 days from systemic steroids.
    4. ≥12 weeks from large field radiation therapy (i.e., total body irradiation, whole abdominal, total lung, ≥50% pelvis).
    5. 6 weeks from prior craniospinal radiotherapy or Iodine-131-metaiodobenzylguanidine (131I-MIBG) therapy.
    6. 2 weeks from radiotherapy to the primary tumor bed.
    7. ≥7 days from small treatment field radiation.
    8. 14 days or 5 half-lives (whichever is longer) from last administration of an IMP.
    9. >7 days prior to study enrollment for drugs that are strong inducers or inhibitors of Cytochrome P450 3A4 (CYP3A4).
    10. ≥21 days and with recovery of all associated toxicities from receiving cellular therapy (e.g., modified T lymphocyte cells, Natural Killer (NK) cells, dendritic cells).
  16. Ongoing need for any medication known or suspected to interfere with study treatment.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Andet: Højere dosis

21-day cycle for a maximum of 12 cycles

Andet: Lavere dosis

21-day cycle for a maximum of 12 cycles

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Overall response rate (ORR)
Tidsramme: Assessed at end of treatment (up to 12 months)

Proportion of participants treated with hu14.18K322A in combination with chemotherapy who achieve a complete response (CR) or partial response (PR) according to the International Neuroblastoma Response Criteria (INRC)

Assessed at end of treatment (up to 12 months)
Metastatic complete response rate (mCRR)
Tidsramme: Assessed at end of treatment (up to 12 months)

Proportion of participants treated with hu14.18K322A in combination with chemotherapy who achieve an overall metastatic complete response (mCR) response

Assessed at end of treatment (up to 12 months)

Sekundære resultatmål

Resultatmål
Tidsramme
Samlet overlevelse (OS)
Tidsramme: Op til 3 år
Op til 3 år
Overall Metastatic Response Rate (mORR)
Tidsramme: (vurderet ved afslutning af behandling (op til 12 måneder))
(vurderet ved afslutning af behandling (op til 12 måneder))
Responsvarighed (DOR)
Tidsramme: Fra tidspunktet for første respons til sygdomsprogression, afbrydelse af studiet, start af ny behandling eller død
Fra tidspunktet for første respons til sygdomsprogression, afbrydelse af studiet, start af ny behandling eller død
Progressionsfri overlevelse (PFS)
Tidsramme: Fra start af cyklus 1 til første forekomst af progression, fulgt i op til 3 år
Fra start af cyklus 1 til første forekomst af progression, fulgt i op til 3 år
Event-Free Survival (EFS)
Tidsramme: Fra start af cyklus 1 indtil første forekomst af progression, sekundær malignitet eller død uanset årsag, fulgt i op til 3 år
Fra start af cyklus 1 indtil første forekomst af progression, sekundær malignitet eller død uanset årsag, fulgt i op til 3 år

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

30. marts 2026

Primær færdiggørelse (Anslået)

1. marts 2031

Studieafslutning (Anslået)

1. marts 2031

Datoer for studieregistrering

Først indsendt

9. april 2026

Først indsendt, der opfyldte QC-kriterier

17. april 2026

Først opslået (Faktiske)

24. april 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

20. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

19. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • EPG-HU1418-201
  • Health Canada (Anden identifikator: 302929)
  • 169169 (Anden identifikator: United States Food and Drug Administration (FDA or USFDA))
  • 2025-524397-42-00 (Anden identifikator: European Union Clinical Trials Regulation (EU CTR), European Medicines Agency (EMA))
  • 1013435 (Anden identifikator: Integrated Research Application System (IRAS), Medicines and Healthcare products Regulatory Agency (MHRA))

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

At the current time there is no plan to share data. We have not received a research proposal that would require utilization of IPD. In the event we receive a request to access IPD a full evaluation will be undertaken and the data will be shared as appropriate and in compliance with the applicable regulations.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .